X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
XORLO (proprietary oxypurinol formulation) is in under development for the treatment of individuals with progressing autosomal dominant polycystic kidney disease (ADPKD).
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: Xorlo
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
XORLO (proprietary oxypurinol formulation) is in under development for the treatment of individuals with progressing autosomal dominant polycystic kidney disease (ADPKD).
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: Xorlo
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
XRx-008 (oxypurinol) inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid, which results in a decrease in the concentrations of uric acid in the blood and urine.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRX-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2023
Details:
XRx-008 (oxypurinol) inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid, which results in a decrease in the concentrations of uric acid in the blood and urine.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
XRx-008 (oxypurinol) inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid, resulting in a decrease in the concentrations of uric acid in the blood and urine.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
XRx-008 (oxypurinol) inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid, which results in a decrease in the concentrations of uric acid in the blood and urine.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
XORTX’s lead program XRx-008 is designed to deliver the xanthine oxidase inhibitor (“XOI”) oxypurinol at concentrations sufficient to substantially inhibit aberrant purine metabolism in the kidneys of individuals with progressing kidney disease due to ADPKD.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
XORTX’s XRx-008 therapeutic development program for ADPKD, is advancing a proprietary composition of xanthine oxidase inhibitor, to manage aberrant purine metabolism and chronically high serum uric acid concentration.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
XRx-008 is designed to deliver xanthine oxidase inhibitor oxypurinol at concentrations sufficient to substantially inhibit aberrant purine metabolism in kidney of individuals with progressing kidney disease due to ADPKD inhibit production of uric acid in circulation.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
The presentation will report that XORTX's XRx-008 (oxypurinol) formulation of Xanthine Oxidase inhibitor can substantially and significantly block the increase in kidney size associated with high circulating uric acid in a rodent model of polycystic kidney disease.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRX-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
